Characteristics of patients based on baseline TMTV ≤220 or >220
| Characteristic, n (%) . | TMTV ≤220 (n = 142) . | TMTV >220 (n = 159) . | P . |
|---|---|---|---|
| Age (y), median (range) | 68 (58-78) | 68 (59-80) | .51 |
| Sex | .02* | ||
| Male | 73 (51) | 103 (65) | |
| Female | 69 (49) | 56 (35) | |
| Histology | .12 | ||
| DLBCL NOS | 98 (69) | 115 (72) | |
| FL grade 3B | 2 (1) | 1 (1) | |
| De novo transformed | 18 (13) | 8 (5) | |
| Other | 16 (11) | 15 (9) | |
| Central review missing | 8 (6) | 20 (13) | |
| ECOG PS | .029 | ||
| 0-1 | 123 (87) | 124 (78) | |
| ≥2 | 16 (11) | 33 (21) | |
| Missing | 3 (2) | 2 (1) | |
| Ann Arbor stage | .043 | ||
| I-II | 18 (13) | 9 (6) | |
| III-IV | 124 (87) | 150 (94) | |
| aaIPI | <.001 | ||
| 0-1 | 85 (60) | 41 (26) | |
| 2-3 | 56 (39) | 115 (72) | |
| Missing | 1 (1) | 3 (2) | |
| IPI | <.001 | ||
| 0-2 | 59 (42) | 23 (15) | |
| 3-5 | 82 (58) | 133 (84) | |
| Missing | 1 (1) | 3 (2) | |
| NCCN-IPI | <.001 | ||
| Low-intermediate | 54 (38) | 22 (14) | |
| High-intermediate | 67 (47) | 101 (64) | |
| High | 10 (7) | 29 (18) | |
| Missing | 11 (8) | 7 (4) | |
| Extranodal sites | <.001 | ||
| ≤1 | 86 (61) | 58 (37) | |
| >1 | 56 (39) | 101 (64) | |
| Elevated LDH (>ULN) | <.001 | ||
| No | 77 (54) | 41 (26) | |
| Yes | 64 (45) | 115 (72) | |
| Missing | 1 (1) | 3 (2) | |
| β2 microglobulin (mg/L) | <.001 | ||
| <3 | 76 (54) | 48 (30) | |
| ≥3 | 33 (23) | 69 (43) | |
| Missing | 33 (23) | 42 (26) | |
| Albumin (g/L) | .005 | ||
| ≤35 | 24 (17) | 47 (30) | |
| >35 | 93 (66) | 77 (48) | |
| Missing | 25 (18) | 35 (22) | |
| R-CHOP induction cycles | .45 | ||
| 6 | 45 (32) | 43 (27) | |
| 8 cycles | 97 (68) | 116 (73) | |
| Response to R-CHOP induction | .99 | ||
| CR | 107 (75) | 119 (75) | |
| PR | 35 (25) | 39 (25) | |
| ORR | 142 (100%) | 158 (99) |
| Characteristic, n (%) . | TMTV ≤220 (n = 142) . | TMTV >220 (n = 159) . | P . |
|---|---|---|---|
| Age (y), median (range) | 68 (58-78) | 68 (59-80) | .51 |
| Sex | .02* | ||
| Male | 73 (51) | 103 (65) | |
| Female | 69 (49) | 56 (35) | |
| Histology | .12 | ||
| DLBCL NOS | 98 (69) | 115 (72) | |
| FL grade 3B | 2 (1) | 1 (1) | |
| De novo transformed | 18 (13) | 8 (5) | |
| Other | 16 (11) | 15 (9) | |
| Central review missing | 8 (6) | 20 (13) | |
| ECOG PS | .029 | ||
| 0-1 | 123 (87) | 124 (78) | |
| ≥2 | 16 (11) | 33 (21) | |
| Missing | 3 (2) | 2 (1) | |
| Ann Arbor stage | .043 | ||
| I-II | 18 (13) | 9 (6) | |
| III-IV | 124 (87) | 150 (94) | |
| aaIPI | <.001 | ||
| 0-1 | 85 (60) | 41 (26) | |
| 2-3 | 56 (39) | 115 (72) | |
| Missing | 1 (1) | 3 (2) | |
| IPI | <.001 | ||
| 0-2 | 59 (42) | 23 (15) | |
| 3-5 | 82 (58) | 133 (84) | |
| Missing | 1 (1) | 3 (2) | |
| NCCN-IPI | <.001 | ||
| Low-intermediate | 54 (38) | 22 (14) | |
| High-intermediate | 67 (47) | 101 (64) | |
| High | 10 (7) | 29 (18) | |
| Missing | 11 (8) | 7 (4) | |
| Extranodal sites | <.001 | ||
| ≤1 | 86 (61) | 58 (37) | |
| >1 | 56 (39) | 101 (64) | |
| Elevated LDH (>ULN) | <.001 | ||
| No | 77 (54) | 41 (26) | |
| Yes | 64 (45) | 115 (72) | |
| Missing | 1 (1) | 3 (2) | |
| β2 microglobulin (mg/L) | <.001 | ||
| <3 | 76 (54) | 48 (30) | |
| ≥3 | 33 (23) | 69 (43) | |
| Missing | 33 (23) | 42 (26) | |
| Albumin (g/L) | .005 | ||
| ≤35 | 24 (17) | 47 (30) | |
| >35 | 93 (66) | 77 (48) | |
| Missing | 25 (18) | 35 (22) | |
| R-CHOP induction cycles | .45 | ||
| 6 | 45 (32) | 43 (27) | |
| 8 cycles | 97 (68) | 116 (73) | |
| Response to R-CHOP induction | .99 | ||
| CR | 107 (75) | 119 (75) | |
| PR | 35 (25) | 39 (25) | |
| ORR | 142 (100%) | 158 (99) |
All data are n (%) unless otherwise stated. Percentages may not sum to 100 because of rounding.
NOS, not otherwise specified; FL, follicular lymphoma; ORR, overall response rate; ULN, upper limit of normal.
Expected to be an artifact of multiple comparisons (no significant interaction was observed between gender and TMTV [P = .36] on PFS analysis).